Among 49 evaluable patients ( 25 in the cilostazol group , 24 in the placebo group ) , the primary endpoint was significantly greater in the cilostazol group compared with the placebo group ( -66.588.6 % vs -17.6140.1 % , respectively , p = 0.009 ) .